 Prostatic Neoplasms
"Prostatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE.
| Descriptor ID |
D011471
|
| MeSH Number(s) |
C04.588.945.440.770 C12.294.260.750 C12.294.565.625 C12.758.409.750
|
| Concept/Terms |
Prostatic Neoplasms- Prostatic Neoplasms
- Prostate Neoplasms
- Neoplasms, Prostate
- Neoplasm, Prostate
- Prostate Neoplasm
- Neoplasms, Prostatic
- Neoplasm, Prostatic
- Prostatic Neoplasm
Prostate Cancer- Prostate Cancer
- Cancer, Prostate
- Cancers, Prostate
- Prostate Cancers
- Cancer of the Prostate
- Prostatic Cancer
- Cancer, Prostatic
- Cancers, Prostatic
- Prostatic Cancers
- Cancer of Prostate
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms".
This graph shows the total number of publications written about "Prostatic Neoplasms" by people in UAMS Profiles by year, and whether "Prostatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 | | 2019 | 13 | 0 | 13 | | 2018 | 6 | 1 | 7 | | 2017 | 11 | 0 | 11 | | 2016 | 19 | 0 | 19 | | 2015 | 9 | 1 | 10 | | 2014 | 9 | 2 | 11 | | 2013 | 9 | 2 | 11 | | 2012 | 7 | 0 | 7 | | 2011 | 12 | 3 | 15 | | 2010 | 22 | 5 | 27 | | 2009 | 5 | 0 | 5 | | 2008 | 15 | 3 | 18 | | 2007 | 11 | 2 | 13 | | 2006 | 17 | 4 | 21 | | 2005 | 13 | 0 | 13 | | 2004 | 7 | 1 | 8 | | 2003 | 8 | 1 | 9 | | 2002 | 9 | 2 | 11 | | 2001 | 4 | 0 | 4 | | 2000 | 7 | 0 | 7 | | 1999 | 3 | 0 | 3 | | 1998 | 3 | 2 | 5 | | 1997 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 1995 | 2 | 0 | 2 | | 1994 | 3 | 0 | 3 | | 1993 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1990 | 0 | 1 | 1 | | 1988 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles over the past ten years.
-
Soong D, Stratford J, Avet-Loiseau H, Bahlis N, Davies F, Dispenzieri A, Sasser AK, Schecter JM, Qi M, Brown C, Jones W, Keats JJ, Auclair D, Chiu C, Powers J, Schaffer M. CNV Radar: an improved method for somatic copy number alteration characterization in oncology. BMC Bioinformatics. 2020 Mar 06; 21(1):98.
-
Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen SE, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas-Camarero S, Caldés T, Caliebe A, Caligo MA, Calvello M, Campbell IG, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, Collaborators GS, Collaborators E, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Puppa LD, Dennis J, Díez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles RA, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadaló L, Foretova L, Fostira F, Fountzilas G, Frost D, García-Barberán V, Garre P, Gauthier-Villars M, Géczi L, Gehrig A, Gerdes AM, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera AM, Hahnen E, Hamann U, Hauke J, Herold N, Hogervorst FBL, Honisch E, Hopper JL, Hulick PJ, Investigators K, Investigators H, Izatt L, Jager A, James P, Janavicius R, Jensen UB, Jensen TD, Johannsson OT, John EM, Joseph V, Kang E, Kast K, Kiiski JI, Kim SW, Kim Z, Ko KP, Konstantopoulou I, Kramer G, Krogh L, Kruse TA, Kwong A, Larsen M, Lasset C, Lautrup C, Lazaro C, Lee J, Lee JW, Lee MH, Lemke J, Lesueur F, Liljegren A, Lindblom A, Llovet P, Lopez-Fernández A, Lopez-Perolio I, Lorca V, Loud JT, Ma ESK, Mai PL, Manoukian S, Mari V, Martin L, Matricardi L, Mebirouk N, Medici V, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller C, Gomes DM, Montagna M, Mooij TM, Moserle L, Mouret-Fourme E, Mulligan AM, Nathanson KL, Navratilova M, Nevanlinna H, Niederacher D, Nielsen FCC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Ong KR, Osorio A, Ott CE, Palli D, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Pérez-Segura P, Peterlongo P, Petersen AH, Porteous ME, Pujana MA, Radice P, Ramser J, Rantala J, Rashid MU, Rhiem K, Rizzolo P, Robson ME, Rookus MA, Rossing CM, Ruddy KJ, Santos C, Saule C, Scarpitta R, Schmutzler RK, Schuster H, Senter L, Seynaeve CM, Shah PD, Sharma P, Shin VY, Silvestri V, Simard J, Singer CF, Skytte AB, Snape K, Solano AR, Soucy P, Southey MC, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Stradella A, Sunde L, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tommasi S, Torres D, Toss A, Trainer AH, Tung N, van Asperen CJ, van der Baan FH, van der Kolk LE, van der Luijt RB, van Hest LP, Varesco L, Varon-Mateeva R, Viel A, Vierstraete J, Villa R, von Wachenfeldt A, Wagner P, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Wieme G, Yadav S, Yannoukakos D, Yoon SY, Zanzottera C, Zorn KK, D'Amico AV, Freedman ML, Pomerantz MM, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Ottini L, Nielsen HR, Rebbeck TR. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
-
Delaka A, Mourmouras N, Zervou-Valvi F, Stravodimos K, Anastasiou I, Delakas D. Predictive value of the bone markers osteocalcin and C-terminal telopeptide for jaw osteonecrosis in high-risk prostate cancer patients on bisphosphonate therapy: A prospective study. Arch Esp Urol. 2019 Nov; 72(9):948-954.
-
Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
-
Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Reply by Authors. J Urol. 2019 11; 202(5):958.
-
Mannan R, Taylor AS, Spratt DE, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathol Res Pract. 2020 Jan; 216(1):152663.
-
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shankar PR, Rajendiran T, Shao X, Lee E, Denton B, Barnett C, Piert M. 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med. 2020 03; 61(3):337-343.
-
Barnett CL, Davenport MS, Montgomery JS, Kunju LP, Denton BT, Piert M. 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis. J Nucl Med. 2019 12; 60(12):1705-1712.
-
Osmany S, Zaheer S, Bartel TB, Johnston M, Peh WM, Barmaky S, Jadvar H. Gallium-68-Labeled Prostate-Specific Membrane Antigen-11 PET/CT of Prostate and Nonprostate Cancers. AJR Am J Roentgenol. 2019 08; 213(2):286-299.
-
Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
-
Deming MS. A Case of Polymyalgia Rheumatica Following Robotic-Assisted Radical Prostatectomy for High-Grade Prostate Cancer. Am J Case Rep. 2019 Apr 07; 20:474-477.
-
Kamel MH, Bimali M, Khalil MI, Eltahawy E, Su L, Bissada NK, Davis R. Regional trends in average years of potential life lost (AYPLL) secondary to prostate cancer deaths among Caucasians and African Americans treated by surgery or radiation. Int Urol Nephrol. 2019 Apr; 51(4):561-569.
-
Shankar PR, Maturen KE, George AK, Borza T, Ellimoottil C, Montgomery JS, Wei JT, Denton BT, Davenport MS. Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients. J Am Coll Radiol. 2019 Oct; 16(10):1385-1392.
-
Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
-
Cox RM, Magi-Galluzzi C, McKenney JK. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update. Adv Anat Pathol. 2018 Nov; 25(6):387-399.
-
Curci NE, Gartland P, Shankar PR, Montgomery JS, Miller DC, George AK, Davenport MS. Long-distance longitudinal prostate MRI quality assurance: from startup to 12 months. Abdom Radiol (NY). 2018 09; 43(9):2505-2512.
-
Hussain SS, Huang SB, Bedolla RG, Rivas P, Basler JW, Swanson GP, Hui-Ming Huang T, Narayanasamy G, Papanikolaou N, Miyamoto H, Yeh IT, Reddick RL, Pollock BH, Ghosh R, Kumar AP. Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation. Cancer Lett. 2018 10 01; 433:232-241.
-
Moser DC, Kaufman MR, Milam DF, Johnsen NV, Cleves MA, Broghammer JA, Brant WO, Jones LA, Brady JD, Gross MS, Jani K, Henry GD. Impact of Radiation and Transcorporeal Artificial Sphincter Placement in Patients with Prior Urethral Cuff Erosion: Results from a Retrospective Multicenter Analysis. J Urol. 2018 12; 200(6):1338-1343.
-
Curci NE, Lane BR, Shankar PR, Noyes SL, Moriarity AK, Kubat A, Brede C, Montgomery JS, Auffenberg GB, Miller DC, Montie JE, George AK, Davenport MS. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance. Urology. 2018 06; 116:137-143.
-
Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 07; 122(1):50-58.
-
Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol. 2018 06; 199(6):1488-1493.
-
Kaufman MR, Milam DF, Johnsen NV, Cleves MA, Broghammer JA, Brant WO, Jones LA, Brady JD, Gross MS, Henry GD. Prior Radiation Therapy Decreases Time to Idiopathic Erosion of Artificial Urinary Sphincter: A Multi-Institutional Analysis. J Urol. 2018 04; 199(4):1037-1041.
-
Kauweloa KI, Gutierrez AN, Bergamo AM, Stathakis S, Papanikolaou N, Mavroidis P. Clinical analysis of the approximate, 3-dimensional, biological effective dose equation in multiphase treatment plans. Med Dosim. 2018 Spring; 43(1):11-22.
-
Mendonca MS, Turchan WT, Alpuche ME, Watson CN, Estabrook NC, Chin-Sinex H, Shapiro JB, Imasuen-Williams IE, Rangel G, Gilley DP, Huda N, Crooks PA, Shapiro RH. DMAPT inhibits NF-?B activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 11; 112:318-326.
-
Mavroidis P, Komisopoulos G, Buckey C, Mavroeidi M, Swanson GP, Baltas D, Papanikolaou N, Stathakis S. Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. Phys Med. 2017 Aug; 40:33-41.
-
Kirby MK, Ramaker RC, Roberts BS, Lasseigne BN, Gunther DS, Burwell TC, Davis NS, Gulzar ZG, Absher DM, Cooper SJ, Brooks JD, Myers RM. Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns. BMC Cancer. 2017 04 17; 17(1):273.
-
Gilbert SM, Dunn RL, Miller DC, Montgomery JS, Skolarus TA, Weizer AZ, Wood DP, Hollenbeck BK. Functional Outcomes Following Nerve Sparing Prostatectomy Augmented with Seminal Vesicle Sparing Compared to Standard Nerve Sparing Prostatectomy: Results from a Randomized Controlled Trial. J Urol. 2017 09; 198(3):600-607.
-
Piert M, Shao X, Raffel D, Davenport MS, Montgomery J, Kunju LP, Hockley BG, Siddiqui J, Scott PJH, Chinnaiyan AM, Rajendiran T. Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. J Nucl Med. 2017 08; 58(8):1216-1223.
-
McClinton C, Niroumand M, Sood S, Shah V, Hill J, Dusing RW, Shen X. Patterns of lymph node positivity on 11C-acetate PET imaging in correlation to the RTOG pelvic radiation field for prostate cancer. Pract Radiat Oncol. 2017 Sep - Oct; 7(5):325-331.
-
Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017 09; 120(3):351-357.
-
Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, Choi YD, Rha KH. Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to =8 among patients with biopsy Gleason score 6. Investig Clin Urol. 2017 03; 58(2):90-97.
-
Zhang X, Penagaricano J, Narayanasamy G, Corry P, Liu T, Sanjay M, Paudel N, Morrill S. Helical tomotherapy to LINAC plan conversion utilizing RayStation Fallback planning. J Appl Clin Med Phys. 2017 Jan; 18(1):178-185.
-
Hussein AA, Ghani KR, Peabody J, Sarle R, Abaza R, Eun D, Hu J, Fumo M, Lane B, Montgomery JS, Hinata N, Rooney D, Comstock B, Chan HK, Mane SS, Mohler JL, Wilding G, Miller D, Guru KA. Development and Validation of an Objective Scoring Tool for Robot-Assisted Radical Prostatectomy: Prostatectomy Assessment and Competency Evaluation. J Urol. 2017 05; 197(5):1237-1244.
-
Jang WS, Kim LH, Yoon CY, Rha KH, Choi YD, Hong SJ, Ham WS. Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical Prostatectomy. PLoS One. 2016; 11(10):e0164497.
-
Katafigioti A, Katafigiotis I, Sfoungaristos S, Alamanis C, Stravodimos K, Anastasiou I, Roumelioti E, Duvdevani M, Constantinides C. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice. Arch Ital Urol Androl. 2016 Oct 05; 88(3):195-200.
-
Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, Choi YD, Rha KH. Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size. BJU Int. 2017 Jan; 119(1):135-141.
-
Allott EH, Arab L, Su LJ, Farnan L, Fontham ET, Mohler JL, Bensen JT, Steck SE. Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. Prostate Cancer Prostatic Dis. 2017 03; 20(1):48-54.
-
Narayanasamy G, Avila G, Mavroidis P, Papanikolaou N, Gutierrez A, Baacke D, Shi Z, Stathakis S. Comparison of composite prostate radiotherapy plan doses with dependent and independent boost phases. Australas Phys Eng Sci Med. 2016 Sep; 39(3):727-33.
-
Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, Kahn VC, Montgomery JS, Greene KL, Zhang B, Ubel PA. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Med Decis Making. 2017 01; 37(1):56-69.
-
Cheong A, Zhang X, Cheung YY, Tang WY, Chen J, Ye SH, Medvedovic M, Leung YK, Prins GS, Ho SM. DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk. Epigenetics. 2016 09; 11(9):674-689.
-
Rizzardi AE, Zhang X, Vogel RI, Kolb S, Geybels MS, Leung YK, Henriksen JC, Ho SM, Kwak J, Stanford JL, Schmechel SC. Quantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor ß2 immunohistochemistry in prostate cancer. Diagn Pathol. 2016 Jul 11; 11(1):63.
-
Antwi SO, Steck SE, Su LJ, Hebert JR, Zhang H, Craft NE, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L. Carotenoid intake and adipose tissue carotenoid levels in relation to prostate cancer aggressiveness among African-American and European-American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate. 2016 09; 76(12):1053-66.
-
Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY, Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol. 2016 09; 34(9):415.e1-6.
-
Spratt DE, Cole AI, Palapattu GS, Weizer AZ, Jackson WC, Montgomery JS, Dess RT, Zhao SG, Lee JY, Wu A, Kunju LP, Talmich E, Miller DC, Hollenbeck BK, Tomlins SA, Feng FY, Mehra R, Morgan TM. Independent surgical validation of the new prostate cancer grade-grouping system. BJU Int. 2016 Nov; 118(5):763-769.
-
Senwar KR, Reddy TS, Thummuri D, Sharma P, Naidu VG, Srinivasulu G, Shankaraiah N. Design, synthesis and apoptosis inducing effect of novel (Z)-3-(3'-methoxy-4'-(2-amino-2-oxoethoxy)-benzylidene)indolin-2-ones as potential antitumour agents. Eur J Med Chem. 2016 Aug 08; 118:34-46.
-
Piert M, Montgomery J, Kunju LP, Siddiqui J, Rogers V, Rajendiran T, Johnson TD, Shao X, Davenport MS. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med. 2016 Jul; 57(7):1065-70.
-
Leach JC, Wang A, Ye K, Jin S. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery. Int J Mol Sci. 2016 Mar 14; 17(3):380.
-
Cole AI, Morgan TM, Spratt DE, Palapattu GS, He C, Tomlins SA, Weizer AZ, Feng FY, Wu A, Siddiqui J, Chinnaiyan AM, Montgomery JS, Kunju LP, Miller DC, Hollenbeck BK, Wei JT, Mehra R. Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. J Urol. 2016 08; 196(2):405-11.
-
Ginat DT, Gluth MB. Pulsatile tinnitus and a temporal bone mass. Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Dec; 133(6):441-442.
-
Vance TM, Wang Y, Su LJ, Fontham ET, Steck SE, Arab L, Bensen JT, Mohler JL, Chen MH, Chun OK. Dietary Total Antioxidant Capacity is Inversely Associated with Prostate Cancer Aggressiveness in a Population-Based Study. Nutr Cancer. 2016; 68(2):214-24.
-
Allott EH, Farnan L, Steck SE, Arab L, Su LJ, Mishel M, Fontham ET, Mohler JL, Bensen JT. Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina-Louisiana Prostate Cancer Project. Cancer Epidemiol Biomarkers Prev. 2016 04; 25(4):670-7.
-
Schade GR, Holt SK, Zhang X, Song D, Wright JL, Zhao S, Kolb S, Lam HM, Levin L, Leung YK, Ho SM, Stanford JL. Prostate Cancer Expression Profiles of Cytoplasmic ERß1 and Nuclear ERß2 are Associated with Poor Outcomes following Radical Prostatectomy. J Urol. 2016 06; 195(6):1760-6.
-
Vance TM, Azabdaftari G, Pop EA, Lee SG, Su LJ, Fontham ET, Bensen JT, Steck SE, Arab L, Mohler JL, Chen MH, Koo SI, Chun OK. Intake of dietary antioxidants is inversely associated with biomarkers of oxidative stress among men with prostate cancer. Br J Nutr. 2016 Jan 14; 115(1):68-74.
-
Magers MJ, Zhan T, Udager AM, Wei JT, Tomlins SA, Wu AJ, Kunju LP, Lew M, Feng FY, Hamstra DA, Siddiqui J, Chinnaiyan AM, Montgomery JS, Weizer AZ, Morgan TM, Hollenbeck BK, Miller DC, Palapattu GS, Jiang H, Mehra R. Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. Med Oncol. 2015 Nov; 32(11):249.
-
Holmes-Rovner M, Montgomery JS, Rovner DR, Scherer LD, Whitfield J, Kahn VC, Merkle EC, Ubel PA, Fagerlin A. Informed Decision Making: Assessment of the Quality of Physician Communication about Prostate Cancer Diagnosis and Treatment. Med Decis Making. 2015 11; 35(8):999-1009.
-
Ho SM, Cheong A, Lam HM, Hu WY, Shi GB, Zhu X, Chen J, Zhang X, Medvedovic M, Leung YK, Prins GS. Exposure of Human Prostaspheres to Bisphenol A Epigenetically Regulates SNORD Family Noncoding RNAs via Histone Modification. Endocrinology. 2015 Nov; 156(11):3984-95.
-
Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015 Jul 22; 6:7736.
-
Kim A, Davis R, Higuchi M. Intracellular oxygen determined by respiration regulates localization of Ras and prenylated proteins. Cell Death Dis. 2015 Jul 16; 6:e1825.
-
Antwi SO, Steck SE, Su LJ, Hébert JR, Zhang H, Fontham ET, Smith GJ, Bensen JT, Mohler JL, Arab L. Dietary, supplement, and adipose tissue tocopherol levels in relation to prostate cancer aggressiveness among African and European Americans: The North Carolina-Louisiana Prostate Cancer Project (PCaP). Prostate. 2015 Sep; 75(13):1419-35.
-
Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015 Jul; 17(4):374-81.
-
Wan F, Small D, Bekelman JE, Mitra N. Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods. Stat Med. 2015 Jun 30; 34(14):2235-65.
-
Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T, Deliveliotis C. Estrogen receptor (a and ß) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 2015 Jan-Feb; 17(1):98-105.
-
Gilbert SM, Dunn RL, Wittmann D, Montgomery JS, Hollingsworth JM, Miller DC, Hollenbeck BK, Wei JT, Montie JE. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer. 2015 May 01; 121(9):1484-91.
-
Shukla P, Mathur V, Kumar A, Khedgikar V, Teja VB, Chaudhary D, Kushwaha P, Bora HK, Konwar R, Trivedi R, Mishra PR. Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis. J Biomed Nanotechnol. 2014 Nov; 10(11):3381-91.
-
Upreti R, Naredo G, Faqehi AM, Hughes KA, Stewart LH, Walker BR, Homer NZ, Andrew R. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5a-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry. Talanta. 2015 Jan; 131:728-35.
-
Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, Creighton CJ, Ittmann M, Ozen M. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int J Cancer. 2015 Feb 15; 136(4):875-9.
-
Jensen AB, Moseley PL, Oprea TI, Ellesøe SG, Eriksson R, Schmock H, Jensen PB, Jensen LJ, Brunak S. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. 2014 Jun 24; 5:4022.
-
Kozminski MA, Palapattu GS, Mehra R, Montgomery JS, Weizer AZ, Skolarus TA, Hollenbeck BK, Miller DC, He C, Tomlins S, Montie JE, Feng FY, Wood DP, Kunju LP, Morgan TM. Understanding the relationship between tumor size, gland size, and disease aggressiveness in men with prostate cancer. Urology. 2014 Aug; 84(2):373-8.
-
Leung YK, Chan QK, Ng CF, Ma FM, Tse HM, To KF, Maranchie J, Ho SM, Lau KM. Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. PLoS One. 2014; 9(5):e98037.
-
Su LJ, Fontham ET. Prostate cancer: an occupational hazard? Future Oncol. 2014 May; 10(6):903-6.
-
Li G, Li M, Zhang Y, Wang D, Li R, Guimerà R, Gao JT, Zhang MQ. ModuleRole: a tool for modulization, role determination and visualization in protein-protein interaction networks. PLoS One. 2014; 9(5):e94608.
-
Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Montgomery JS, Weizer AZ, Hollenbeck BK. Adherence to performance measures and outcomes among men treated for prostate cancer. J Urol. 2014 Sep; 192(3):743-8.
-
Mavroidis P, Milickovic N, Cruz WF, Tselis N, Karabis A, Stathakis S, Papanikolaou N, Zamboglou N, Baltas D. Comparison of different fractionation schedules toward a single fraction in high-dose-rate brachytherapy as monotherapy for low-risk prostate cancer using 3-dimensional radiobiological models. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):216-23.
-
Schroeck FR, Kaufman SR, Jacobs BL, Zhang Y, Weizer AZ, Montgomery JS, Gilbert SM, Strope SA, Hollenbeck BK. The impact of technology diffusion on treatment for prostate cancer. Med Care. 2013 Dec; 51(12):1076-84.
-
Itah Z, Oral O, Perk OY, Sesen M, Demir E, Erbil S, Dogan-Ekici AI, Ekici S, Kosar A, Gozuacik D. Hydrodynamic cavitation kills prostate cells and ablates benign prostatic hyperplasia tissue. Exp Biol Med (Maywood). 2013 Nov 01; 238(11):1242-50.
-
Penugonda K, Lindshield BL. Fatty acid and phytosterol content of commercial saw palmetto supplements. Nutrients. 2013 Sep 13; 5(9):3617-33.
-
Daniels J, Kadlubar S. Sulfotransferase genetic variation: from cancer risk to treatment response. Drug Metab Rev. 2013 Nov; 45(4):415-22.
-
Lee MT, Ouyang B, Ho SM, Leung YK. Differential expression of estrogen receptor beta isoforms in prostate cancer through interplay between transcriptional and translational regulation. Mol Cell Endocrinol. 2013 Aug 25; 376(1-2):125-35.
-
Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem. 2013 Jun 27; 56(12):4880-98.
-
Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, Clair DK, Clair WH. KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res. 2013 Jul 15; 73(14):4406-17.
-
Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK. Technology diffusion and diagnostic testing for prostate cancer. J Urol. 2013 Nov; 190(5):1715-20.
-
Shenoi MM, Iltis I, Choi J, Koonce NA, Metzger GJ, Griffin RJ, Bischof JC. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013 May 06; 10(5):1683-94.
-
Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D, Machan L, Black P. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. BJU Int. 2013 May; 111(6):946-53.
-
Tripathi S, Glazko GV, Emmert-Streib F. Ensuring the statistical soundness of competitive gene set approaches: gene filtering and genome-scale coverage are essential. Nucleic Acids Res. 2013 Apr; 41(7):e82.
-
DeLancey JO, Wood DP, He C, Montgomery JS, Weizer AZ, Miller DC, Jacobs BL, Montie JE, Hollenbeck BK, Skolarus TA. Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology. 2013 Feb; 81(2):354-7.
-
Knaup C, Mavroidis P, Esquivel C, Stathakis S, Swanson G, Baltas D, Papanikolaou N. Investigating the dosimetric and tumor control consequences of prostate seed loss and migration. Med Phys. 2012 Jun; 39(6):3291-8.
-
Arab L, Su LJ, Steck SE, Ang A, Fontham ET, Bensen JT, Mohler JL. Coffee consumption and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Nutr Cancer. 2012; 64(5):637-42.
-
Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012; 15(4):712-23.
-
Sucheston LE, Bensen JT, Xu Z, Singh PK, Preus L, Mohler JL, Su LJ, Fontham ET, Ruiz B, Smith GJ, Taylor JA. Genetic ancestry, self-reported race and ethnicity in African Americans and European Americans in the PCaP cohort. PLoS One. 2012; 7(3):e30950.
-
Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl DM, Eng C. Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res. 2012 Mar 15; 18(6):1578-87.
-
Cook CC, Kim A, Terao S, Gotoh A, Higuchi M. Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis. 2012 Jan 19; 3:e258.
-
Arrington MI. A walk across campus on a windy day: barriers to prostate cancer testing. Health Commun. 2012; 27(4):408-9.
-
Song L, Mishel M, Bensen JT, Chen RC, Knafl GJ, Blackard B, Farnan L, Fontham E, Su LJ, Brennan CS, Mohler JL, Godley PA. How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer? Findings from the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer. 2012 Aug 01; 118(15):3842-51.
-
Jacobs BL, Montgomery JS, Dunn RL, Weizer AZ, Miller DC, Wood DP, Wolf JS, Zhang Y, Wei JT, Hollenbeck BK. A comparison of extraperitoneal and intraperitoneal approaches for robotic prostatectomy. Surg Innov. 2012 Sep; 19(3):268-74.
-
Ho SM, Lee MT, Lam HM, Leung YK. Estrogens and prostate cancer: etiology, mediators, prevention, and management. Endocrinol Metab Clin North Am. 2011 Sep; 40(3):591-614, ix.
-
Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 2011 Nov; 76(12):1268-79.
-
Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23.
-
Leung YK, Ho SM. Estrogen receptor ß: switching to a new partner and escaping from estrogen. Sci Signal. 2011 Apr 12; 4(168):pe19.
-
Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT, Mohler JL. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev. 2011 May; 20(5):844-53.
-
Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. Anticancer Res. 2011 Apr; 31(4):1475-82.
-
Ojha RP, Felini MJ, Singh KP, Faramawi MF, Thertulien R. Radiation therapy for localized or locally advanced prostate adenocarcinoma and myeloma incidence in a population-based cohort. BJU Int. 2011 Mar; 107(5):693-7.
-
Morgan GJ. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S24-30.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|